UPDATED: In a fresh disappointment, Amgen spotlights a major safety issue with KRAS combo
Amgen had hoped that its latest study matching its landmark KRAS G12C drug Lumakras with checkpoint inhibitors would open up its treatment horizons and expand its commercial potential. Instead, the combo spurred safety issues that blunted efficacy and forced the pharma giant to alter course on its treatment strategy, once again disappointing analysts who have been tracking the drug’s faltering sales and limited therapeutic reach.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.